Raub Brock Capital Management LP Lowers Stock Position in Eli Lilly and Company $LLY

Raub Brock Capital Management LP reduced its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.3% in the fourth quarter, Holdings Channel reports. The fund owned 21,180 shares of the company’s stock after selling 720 shares during the quarter. Eli Lilly and Company accounts for about 5.1% of Raub Brock Capital Management LP’s portfolio, making the stock its 4th largest position. Raub Brock Capital Management LP’s holdings in Eli Lilly and Company were worth $22,762,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Royal Fund Management LLC raised its holdings in shares of Eli Lilly and Company by 4.4% in the 4th quarter. Royal Fund Management LLC now owns 4,685 shares of the company’s stock worth $5,035,000 after purchasing an additional 197 shares during the period. Range Financial Group LLC lifted its stake in Eli Lilly and Company by 6.9% in the fourth quarter. Range Financial Group LLC now owns 5,124 shares of the company’s stock valued at $5,506,000 after purchasing an additional 329 shares during the last quarter. Alpine Bank Wealth Management grew its holdings in Eli Lilly and Company by 25.6% during the fourth quarter. Alpine Bank Wealth Management now owns 1,366 shares of the company’s stock valued at $1,468,000 after purchasing an additional 278 shares during the period. 4J Wealth Management LLC purchased a new stake in Eli Lilly and Company in the fourth quarter worth $239,000. Finally, Silver Oak Securities Incorporated increased its position in Eli Lilly and Company by 6.4% in the fourth quarter. Silver Oak Securities Incorporated now owns 4,628 shares of the company’s stock worth $4,997,000 after buying an additional 279 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $935.85 on Friday. The business’s fifty day moving average is $996.24 and its 200 day moving average is $966.65. The firm has a market cap of $884.21 billion, a price-to-earnings ratio of 40.78, a PEG ratio of 1.11 and a beta of 0.51. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping the consensus estimate of $7.48 by $0.06. The business had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm’s revenue was up 42.6% compared to the same quarter last year. During the same quarter last year, the company earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of recent research reports. Freedom Capital raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 10th. Daiwa Securities Group lifted their price objective on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Zacks Research cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Barclays started coverage on shares of Eli Lilly and Company in a report on Thursday, February 19th. They set an “overweight” rating and a $1,350.00 price objective on the stock. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Eli Lilly and Company in a research note on Friday, March 27th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $1,222.22.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approved Lilly’s oral GLP‑1 weight‑loss pill Foundayo (orforglipron), enabling a commercial launch (via LillyDirect) and broader patient access—this is the main growth catalyst behind recent investor enthusiasm. FDA approves Lilly’s Foundayo (PR Newswire)
• Positive Sentiment: Bank of America and other sell‑side notes see Foundayo as a durable commercial opportunity (BofA called it a preferred oral GLP‑1); BofA also raised its price target and reiterated a Buy rating, supporting medium‑term analyst optimism. Bank of America sees Foundayo as preferred oral GLP-1
• Positive Sentiment: Street estimates see a multi‑billion dollar debut for Foundayo (analyst scenarios ~ $1.5B–$2.8B in 2026) and unusually large call‑option activity indicates speculative positioning for further upside from the drug launch. Foundayo Launch Could Drive Up to $2.8B (Blockonomi)
• Neutral Sentiment: Lilly agreed to acquire Centessa (deal value reported around $7.8B), diversifying Lilly’s pipeline into sleep/neuroscience — strategic for long‑term growth but adds near‑term integration and price‑premium risk. LLY to Buy Centessa Pharmaceuticals (Zacks)
• Negative Sentiment: Policy risk: the Trump administration is proposing steep tariffs on branded drugs for companies that haven’t struck pricing deals—this raises regulatory and margin uncertainty for big pharma, including Lilly. Trump Administration Unveils Up to 100% Tariff on Branded Drugs (WSJ)
• Negative Sentiment: Competitive/marketing noise: Novo Nordisk published cross‑trial comparisons claiming its oral Wegovy outperformed Foundayo, and media debate over efficacy/side‑effect differences is tempering some investor enthusiasm. Novo says Wegovy pill outperforms Lilly’s Foundayo (CNBC)

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.